Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C

Altunok, Elif; SAYAN, MURAT; AKHAN, SILA; AYGEN, BİLGEHAN; YILDIZ, ORHAN; Koruk, Suda; Mistik, Resit; Demirturk, Nese; Ural, Onur; Kose, ŞÜKRAN; Aynioglu, Aynur; Korkmaz, Fatime; Ersoz, Gulden; Tuna, Nazan; Ayaz, Celal; Karakecili, Faruk; Keten, Derya; Inan, Dilara; Yazici, Saadet; Koculu, Safiye; Yildirmak, Taner

doi:10.1016/j.ijid.2016.07.003

Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C

Copy For Citation

Altunok E. S., SAYAN M., AKHAN S., AYGEN B., YILDIZ O., Koruk S. T., ...More

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol.50, pp.1-5, 2016 (SCI-Expanded)

Publication Type: Article / Article
Volume: 50
Publication Date: 2016
Doi Number: 10.1016/j.ijid.2016.07.003
Journal Name: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1-5
Keywords: Baseline resistance, hepatitis C virus, mutation, protease inhibitors, GENOTYPE 1, PEGYLATED INTERFERON, ANTIVIRAL AGENTS, VIRUS GENOTYPES, RIBAVIRIN, TELAPREVIR, SIMEPREVIR, INFECTION, POLYMORPHISMS, RETREATMENT
Dokuz Eylül University Affiliated: No

Abstract

Background: Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals.